A man with melanoma in the brain stops moving and speaking
Original title: Catatonic signs during delirium in leptomeningeal melanoma: Treatment trade-offs in end-of-life care.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is one person's case written up by their doctors, not a tested treatment.
The short version
Doctors describe the hard choices in caring for one man whose brain cancer left him unable to move or speak.
What was studied. Doctors wrote up the care of one man in his late 30s. He had melanoma that had spread to his brain and the thin layers covering it. They checked him again and again and tracked each medicine they gave.
What they found. He drifted in and out of alertness, stopped speaking, and held still with a blank stare. After lorazepam through a vein, his catatonia score went from 7 to 1. But he was sleepy, so that score was hard to trust. His speech and movement got a little better for a short time, but his attention, eating, and daily function did not. Lorazepam was stopped when he became very agitated, and regular haloperidol helped his evening agitation.
What this means, and what it doesn't
What it could mean: Signs of catatonia can show up in people with advanced cancer in the brain. A better score on a test does not always mean the person is really doing better. Care teams need to watch alertness, attention, eating, and comfort, and ask the patient and family what matters most.
What it doesn't mean: This is one man's story, not a study of many people. It does not prove that lorazepam or haloperidol will help anyone else. These medicines do not treat melanoma, and this is not a cure. Nothing here should change your own care. Talk with your care team about any change like this.
Source: PubMed, November 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.